CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
Arthur Klausner to be a featured speaker at CED Biotech Forum: Trends in Exit Strategies.
News | 06. 18. 2007
